(Total Views: 560)
Posted On: 10/29/2024 7:38:42 AM
Post# of 153903
Someone asked me about Multiple Sclerosis and leronlimab -
Multiple Sclerosis is an autoimmune disease where the myelin sheath covering the nerve fibers and the fibers themselves are damaged by heavily activated microglia and macrophages. That activation and movement to the myelin sheath is driven by the binding of ligands to CCR5 and other immune activation receptors upregulating inflammatory cytokines and increasing immune response. CCR5 is the CCR receptor with the highest expression and most responsible for an overactive immune response.
Leronlimab by blocking CCR5 downregulates a wide range of those inflammatory cytokines and would lower the overactive immune response seen in MS. Leronlimab's lack of serious adverse events in over 1,000 patients is also a plus.
Leronlimab Regulator List (a work in progress)
https://investorshangout.com/post/view?id=6700464
Shows results with leronlimab for some of the inflammatory proteins that it controls -
Leronlimab, mAb to CCR5, Trims Liver Fat in 14-Week Trial of NASH Patients
https://www.natap.org/2022/EASL/EASL_70.htm
CCR5 knockout suppresses experimental autoimmune encephalomyelitis in C57BL/6 mice
https://www.oncotarget.com/article/8097/text/
CCR5+ and CXCR3+ T cells are increased in multiple sclerosis and their ligands MIP-1α and IP-10 are expressed in demyelinating brain lesions
https://pmc.ncbi.nlm.nih.gov/articles/PMC22009/
Multiple Sclerosis is an autoimmune disease where the myelin sheath covering the nerve fibers and the fibers themselves are damaged by heavily activated microglia and macrophages. That activation and movement to the myelin sheath is driven by the binding of ligands to CCR5 and other immune activation receptors upregulating inflammatory cytokines and increasing immune response. CCR5 is the CCR receptor with the highest expression and most responsible for an overactive immune response.
Leronlimab by blocking CCR5 downregulates a wide range of those inflammatory cytokines and would lower the overactive immune response seen in MS. Leronlimab's lack of serious adverse events in over 1,000 patients is also a plus.
Leronlimab Regulator List (a work in progress)
https://investorshangout.com/post/view?id=6700464
Shows results with leronlimab for some of the inflammatory proteins that it controls -
Leronlimab, mAb to CCR5, Trims Liver Fat in 14-Week Trial of NASH Patients
https://www.natap.org/2022/EASL/EASL_70.htm
CCR5 knockout suppresses experimental autoimmune encephalomyelitis in C57BL/6 mice
https://www.oncotarget.com/article/8097/text/
CCR5+ and CXCR3+ T cells are increased in multiple sclerosis and their ligands MIP-1α and IP-10 are expressed in demyelinating brain lesions
https://pmc.ncbi.nlm.nih.gov/articles/PMC22009/
(21)
(0)
